47 completed, 4 recruiting, 3 withdrawn, 2 terminated. 59 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 59 | Completed 47, Recruiting 4, Withdrawn 3, Terminated 2, Enrolling by invitation 1, Not yet recruiting 1, Suspended 1 |
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
Follow ADHD: new trials by email Literature Review of ADHD trials Research Report on ADHD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD Solriamfetol - ADHD | Phase 3 | Enrolling by invitation | Axsome Therapeutics, Inc. | 300 | 2026-08-06 | 2026-10-13 |
| Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2) Solriamfetol Dose A, Solriamfetol Dose B, Placebo - ADHD | Phase 3 | Recruiting | Axsome Therapeutics, Inc. | 468 | 2026-07-06 | 2026-10-13 |
| A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD AK-D101, Placebo - Attention Deficit Hyperactivity Disorder, Attention-Deficit / Hyperactivity Disorder | Phase 3 | Not yet recruiting | Alvogen Korea | 156 | 2026-07-01 | 2026-07-02 |
| Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3) Solriamfetol Dose A, Solriamfetol Dose B, Placebo - ADHD | Phase 3 | Recruiting | Axsome Therapeutics, Inc. | 468 | 2026-06-25 | 2026-10-13 |
| P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety Centanafadine, Placebo - ADHD, Anxiety | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 315 | 2025-03-26 | 2026-05-06 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD AK0901 capsule, Placebo - ADHD | Phase 3 | Completed | Shanghai Ark Biopharmaceutical Co., Ltd. | 55 | 2024-05-28 | 2026-06-22 |
| Benefits of ADHD Treatment in Detained People Concerta, Placebo - ADHD | Phase 3 | Recruiting | Stéphanie Baggio | 150 | 2024-01-01 | 2026-09-21 |
| Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301 CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose) - ADHD, Attention Deficit Hyperactivity Disorder | Phase 3 | Completed | Cingulate Therapeutics | 103 | 2023-08-01 | 2026-01-22 |
| Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301 CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg - ADHD, ADHD - Combined Type | Phase 3 | Suspended | Cingulate Therapeutics | 45 | 2023-07-31 | 2026-05-05 |
| A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo - ADHD | Phase 3 | Completed | Axsome Therapeutics, Inc. | 516 | 2023-07-06 | 2026-02-10 |
| Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD) NRCT-101-SR, Placebo - ADHD | Phase 2 / Phase 3 | Completed | Neurocentria, Inc. | 223 | 2023-02-25 | 2025-06-03 |
| Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301. CTx-1301 - Dexmethylphenidate 25mg, CTx-1301 - Dexmethylphenidate 37.5mg, CTx-1301 - Dexmethylphenidate 50mg - ADHD, ADHD - Combined Type | Phase 3 | Completed | Cingulate Therapeutics | 26 | 2022-12-29 | 2026-07-02 |
| Effectiveness of a Digital Strategy-based Educational Skills Group for Secondary Students With Organization and Academic Motivation Challenges BPT/OST, Peer Support - ADHD | Phase 2 / Phase 3 | Withdrawn | Seattle Children's Hospital | 2022-05-18 | 2026-04-24 | |
| Treating Parents With ADHD and Their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation Trial Behavioral Parent Training, Extended release mixed amphetamine salts (MAS) - ADHD, Parenting | Phase 3 | Completed | University of Maryland, College Park | 269 | 2020-08-06 | 2026-09-16 |
| Effect of Probiotics on ADHD Placebo, BF688 - ADHD, Probiotics | Phase 3 | Completed | Wang Liang-Jen | 150 | 2020-05-14 | 2023-04-06 |
| Classroom Study of SPN-812 in Children With ADHD Placebo, 200 mg SPN-812 - ADHD | Phase 3 | Withdrawn | Supernus Pharmaceuticals, Inc. | 2019-08-01 | 2019-09-18 | |
| Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD AMPH ER Tab 5, 10, 15 and 20 mg, AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg - ADHD | Phase 3 | Completed | Tris Pharma, Inc. | 130 | 2019-02-06 | 2023-11-02 |
| Role of Coenzyme Q in ADHD in Children Atomoxetine, Coenzyme Q - ADHD | Phase 3 | Recruiting | Sherief Abd-Elsalam | 40 | 2018-11-01 | 2020-01-02 |
| PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) PRC-063 oral capsules, Placebo oral capsules - ADHD | Phase 3 | Completed | Purdue Pharma, Canada | 288 | 2018-08-21 | 2021-07-26 |
| KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD KP415 oral capsule - ADHD | Phase 3 | Completed | Zevra Therapeutics | 282 | 2018-03-13 | 2021-07-19 |
Showing 20 of 59. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (59) · Impulsive Behavior (2) · Spasm (2) · Anxiety Disorders (1) · Cocaine-Related Disorders (1) · Generalized Anxiety Disorder (1) · Motor Skills Disorders (1) · Opioid-Related Disorders (1) · Phobia, Social (1) · Recidivism (1) · Smoking (1) · Substance-Related Disorders (1) · Treatment Adherence and Compliance (1)
Attention Deficit and Disruptive Behavior Disorders (59) · Mental Disorders (59) · Neurodevelopmental Disorders (59) · Behavior (4) · Chemically-Induced Disorders (2) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Neuromuscular Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Criminal Behavior (1) · Health Behavior (1) · Narcotic-Related Disorders (1) · Phobic Disorders (1) · Substance-Related Disorders (1)
Methylphenidate (11) · Lisdexamfetamine Dimesylate (5) · Dexmethylphenidate Hydrochloride (3) · Guanfacine (2) · Modafinil (2) · serdexmethylphenidate and dexmethylphenidate (2) · solriamfetol (2) · Atomoxetine Hydrochloride (1) · Behavior Therapy (1) · Bupropion (1) · Central Nervous System Stimulants (1) · Double-Blind Method (1) · Nurse Clinicians (1) · Olive Oil (1) · Random Allocation (1)
Shire (9) · Rhodes Pharmaceuticals, L.P. (5) · Supernus Pharmaceuticals, Inc. (5) · Axsome Therapeutics, Inc. (4) · Cingulate Therapeutics (3) · Novartis (3) · Cephalon (2) · Noven Therapeutics (2) · Purdue Pharma, Canada (2) · University of Cincinnati (2) · Zevra Therapeutics (2) · Addrenex Pharmaceuticals, Inc. (1) · Alcobra Ltd. (1) · Alvogen Korea (1) · Florida International University (1)
United States (44) · Germany (6) · Belgium (3) · Canada (3) · France (2) · Hungary (2) · Italy (2) · Poland (2) · Sweden (2) · Switzerland (2) · United Kingdom (2) · China (1) · Egypt (1) · Israel (1) · Netherlands (1)
Ann Childress, MD (4) · Joseph Reiz (3) · Jonathan Rubin, MD (2) · Matt Brams, MD (2) · Michael Huss, Prof. Dr. (2) · Sailaja Bhaskar, PhD (2) · Sharon B. Wigal, Ph.D. (2) · Stefan Schwabe, MD (2) · Theresa Winhusen, Ph.D. (2) · Wei-wei Chang, Ph.D. (2) · Abeer Salamah, Lecturer (1) · Andrea Chronis-Tuscano, Ph.D. (1) · Andrew J. Cutler, MD (1) · Eugene Somoza, M.D., Ph.D. (1)
PMID 33600233, PMID 33971070, PMID 34523063, PMID 36847750, PMID 34057707, PMID 34637343, PMID 34714112, PMID 16102908, PMID 16678648, PMID 19508731, PMID 20219292, PMID 20492837, PMID 20576091, PMID 20625364, PMID 20806988, PMID 20861583, PMID 20973707, PMID 21156071, PMID 21566420, PMID 21973229, PMID 22176941, PMID 22753087, PMID 22889694, PMID 22955246, PMID 23332456, PMID 23339731, PMID 23410138, PMID 23708466, PMID 23893527, PMID 24229749, PMID 24839883, PMID 25139785, PMID 25245353, PMID 25470572, PMID 25659348, PMID 25877989, PMID 26272693, PMID 26409610, PMID 28351412, PMID 29370538, PMID 31473291, PMID 32723670, PMID 33090921, PMID 33750646, PMID 34189995, PMID 34366928, PMID 34571023, PMID 34819012, PMID 35857716, PMID 36809150
2008 (2), U10DA013732 (2), R01DA011444 (1), R01MH118313 (1)